Rheumatoid Arthritis Market Analysis, Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight
(Albany, US) DelveInsight launched a new report on Rheumatoid Arthritis Market Insights, Epidemiology and Market Forecast-2030
DelveInsight's "Rheumatoid Arthritis - Market
Insights, Epidemiology, and Market Forecast-2030" report delivers
an in-depth understanding of the Rheumatoid Arthritis, historical and
forecasted epidemiology as well as the Rheumatoid Arthritis market trends in
the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and
Japan.
Some
of the key facts of the report
·
One in 12 women and 1 in 20 men will develop an
inflammatory autoimmune rheumatic disease during their lifetime.
·
About 1.5 million in the US have Rheumatoid
Arthritis with a prevalence of 0.6%.
·
Japan has the lowest percentage of prevalent
diagnosed and treated patients.
·
The peak age at Rheumatoid Arthritis onset
shifted from the 50–59 years age group to the 60–69 years age group over the
last decade
View Report: https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-market
1. Rheumatoid Arthritis market report covers a descriptive
overview and comprehensive insight of the Rheumatoid Arthritis epidemiology and
Rheumatoid Arthritis market in the 7 MM (United States, EU5 (Germany, Spain,
France, Italy, UK) & Japan.)
2. Rheumatoid Arthritis market report provides insights on
the current and emerging therapies.
3. Rheumatoid Arthritis market report provides a global
historical and forecasted market covering drug outreach in 7 MM.
4. Rheumatoid Arthritis market report offers an edge that
will help in developing business strategies by understanding trends shaping and
driving the Rheumatoid Arthritis market.
View Report: https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-market
Request for sample pages:
https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market
"Women are affected by Rheumatoid Arthritis three times more than
men."
Rheumatoid
Arthritis treatment landscape has progressed from the last two
decade, including the diagnosis and treatment. Albeit, presently there is no
cure for the disease, the goals of therapy are to decrease pain, inflammation
control, preserve the ability of the patient to function in activities of daily
living and work and avert joint destruction. Pharmacists and other healthcare
professionals play a vital role in caring for Rheumatoid Arthritis patients.
The pharmacologic approaches have relied on combinations of non-steroidal
anti-inflammatory drugs (NSAIDs), analgesics, glucocorticoids (prednisone,
methylprednisone), disease-modifying anti-rheumatic drugs (DMARDs) and
biologics.
Corticosteroids, including prednisone, prednisolone and
methylprednisolone, are potent and quick-acting anti-inflammatory medications.
They may be used to get potentially damaging inflammation under control and may
be needed to control severe polyarticular disease until disease-modifying
antirheumatic drugs (DMARDs) have been added and become useful.
There is now a better comprehension of the mechanisms/pathways involved in the
disease, permitting site-specific drug development. There are two major types
of Disease-Modifying Antirheumatic Drugs (DMARDs): biological and synthetic.
Conventional, synthetic DMARDs (csDMARDs) are not
site-specific, and they do not have precise mechanisms of action for relieving
the disease. Synthetic DMARDs targets to a particular site. Biological DMARDs
are also site-specific (e.g., targeting TNF, IL-6, IL-1, B cells, or T cells).
Request for sample
pages: https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market
View Report: https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-market
The launch of the emerging therapies is expected to significantly impact
Rheumatoid Arthritis treatment scenario in the upcoming years:-
·
Filgotinib
·
Olokizumab
·
ABX464
·
And many others
The
key players in Rheumatoid Arthritis market are:
·
Galapagos NV/Gilead Sciences
·
R-Pharm
·
Abivax
·
And many others
Request for sample
pages: https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market
View Report: https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-market
1. Report Introduction
2. Rheumatoid Arthritis Market Overview at a Glance
3. Rheumatoid Arthritis Disease Background and Overview
4. Rheumatoid Arthritis Epidemiology and Patient Population
5. Rheumatoid Arthritis Country-Wise Epidemiology
6. United States
7. EU–5 Countries
7.1. Assumptions and Rationale
7.2. Germany
7.3. France
7.4. Italy
7.5. Spain
7.6. United Kingdom
7.7. Japan
8. Rheumatoid Arthritis Treatments and Medical Practices
9. Rheumatoid Arthritis Emerging Therapies
10. Key Cross Competition
10.1. Filgotinib: Galapagos NV/Gilead Sciences
10.2. Olokizumab: R-Pharm
11. Rheumatoid Arthritis Market Size
12. 7MM Rheumatoid Arthritis Country-Wise Market Analysis
13. United States Market Size
14. EU5 Market Size
14.1. Germany Market Size
14.2. France Market Size
14.3. Italy Market Size
14.4. Spain Market Size
14.5. UK Market Size
15. Japan Market Size
16. Rheumatoid Arthritis Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight
Request For Detailed
TOC: https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market
View Report: https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused
exclusively on life sciences. It supports pharma companies by providing end to
end comprehensive solutions to improve their performance.
Contact us:
info@delveinsight.com
+919650213330
SOURCE DelveInsight
Rheumatoid Arthritis market,Rheumatoid Arthritis market
research,Rheumatoid Arthritis Companies,Rheumatoid Arthritis market trends,Rheumatoid
Arthritis market forecast,Rheumatoid Arthritis market share,Rheumatoid
Arthritis pipeline,Rheumatoid Arthritis treatment algorithm,Rheumatoid
Arthritis drugs,Rheumatoid Arthritis sales forecasting,Rheumatoid Arthritis
market size,Rheumatoid Arthritis disease,Rheumatoid Arthritis epidemiology,Rheumatoid
Arthritis
Comments
Post a Comment